Headache News and Research RSS Feed - Headache News and Research

Four commonly used medications to treat pregnant women with migraines may not be safe

Four commonly used medications to treat pregnant women with migraines may not be safe

According to doctors at Wake Forest Baptist Medical Center, medications and treatments long considered safe to treat pregnant women with migraines may not be. [More]
IUPUI assistant professor to study role of deficient pain modulatory systems on post-traumatic headaches

IUPUI assistant professor to study role of deficient pain modulatory systems on post-traumatic headaches

An assistant professor in the Department of Kinesiology in the IU School of Physical Education and Tourism Management at Indiana University-Purdue University Indianapolis has been awarded a grant to study the role of deficient pain modulatory systems on chronic post-traumatic headaches afflicting hundreds of thousands of people with mild traumatic brain injuries. [More]
Concussion-related symptoms improve following initial session of OMT

Concussion-related symptoms improve following initial session of OMT

Two case reports published in The Journal of the American Osteopathic Association document improvements in concussion-related symptoms following an initial session of osteopathic manipulative treatment (OMT). [More]
UCI researchers get $8 million to help develop new vaccine for Q fever

UCI researchers get $8 million to help develop new vaccine for Q fever

A University of California, Irvine scientific team led by infectious diseases researchers Philip Felgner and Aaron Esser-Kahn has received $8 million from the U.S. Department of Defense's Defense Threat Reduction Agency to help develop a new vaccine for Q fever. [More]
Yellow fever outbreak in Angola kills 178 people

Yellow fever outbreak in Angola kills 178 people

Angola is grappling with a yellow fever outbreak, which has infected more than 450 people and killed 178 – the first epidemic of the disease to hit the country in 30 years. [More]
Kids with minor head injuries may not require hospitalization, study suggests

Kids with minor head injuries may not require hospitalization, study suggests

Challenging the longstanding practice of keeping all children with head injuries in the hospital overnight, new research from Ann & Robert H. Lurie Children's Hospital suggests that patients with simple skull fractures can be sent home safely if they have no evidence of brain injury and no neurological symptoms. [More]
Sandia engineers aim to develop autonomous device to passively monitor mosquito-borne diseases

Sandia engineers aim to develop autonomous device to passively monitor mosquito-borne diseases

Mosquitoes are deadly efficient at spreading disease. Despite vaccines and efforts to eradicate the pesky insects, they continue to infect humans with feared diseases like Zika virus, malaria and West Nile virus. [More]
Anthim (obiltoxaximab) injection approved for treatment of inhalational anthrax

Anthim (obiltoxaximab) injection approved for treatment of inhalational anthrax

On Friday, March 18, the U.S. Food and Drug Administration approved Anthim (obiltoxaximab) injection to treat inhalational anthrax in combination with appropriate antibacterial drugs. Anthim is also approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate. [More]
Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Inc. today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe. [More]
Hemispheric and thalamic volumes point to electrical epilepticus during sleep

Hemispheric and thalamic volumes point to electrical epilepticus during sleep

Early assessment of hemispheric and thalamic volumes in children with polymicrogyria and epilepsy can reliably predict the risk of continuous spike-and-wave complexes during sleep, a study indicates. [More]
New FDA approval expands use of AstraZeneca's Faslodex for women with HR+, HER2- metastatic breast cancer

New FDA approval expands use of AstraZeneca's Faslodex for women with HR+, HER2- metastatic breast cancer

AstraZeneca today announced that the US Food and Drug Administration has approved a new indication in the US, expanding the use of Faslodex (fulvestrant) to include use in combination with Ibrance (palbociclib). [More]
Idelvion approved for use in children and adults with Hemophilia B

Idelvion approved for use in children and adults with Hemophilia B

The U.S. Food and Drug Administration today approved Idelvion, Coagulation Factor IX (Recombinant), Albumin Fusion Protein, for use in children and adults with Hemophilia B. Idelvion is the first coagulation factor-albumin fusion protein product to be approved, and the second Factor IX fusion protein product approved in the U.S. that is modified to last longer in the blood. [More]
Pregnant women with acute migraine more likely to experience adverse birth outcomes

Pregnant women with acute migraine more likely to experience adverse birth outcomes

Women who have acute migraine attacks that are severe enough to prompt them to seek care may be more likely to have complications when giving birth, including preterm delivery, preeclampsia and low birthweight. Women 35 and older were seven times more likely to have these complications. [More]
Antidepressant paroxetine suppresses inflammation in people with HIV-related cognitive impairment

Antidepressant paroxetine suppresses inflammation in people with HIV-related cognitive impairment

In a small, placebo-controlled clinical trial, Johns Hopkins physicians report that the antidepressant paroxetine modestly improves decision-making and reaction time, and suppresses inflammation in people with HIV-associated cognitive impairment. The researchers say they believe this is the first time that a SSRI (selective serotonin reuptake inhibitor) has been shown to improve key measures of cognition in people with HIV in a controlled study. [More]
Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that it has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration seeking approval for the use of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] to treat children under the age of 12 with hemophilia A and for use in surgical settings. [More]
Study: Most Ebola survivors experience brain symptoms more than six months after initial infection

Study: Most Ebola survivors experience brain symptoms more than six months after initial infection

Most of the 82 Ebola survivors in a new study from the world's largest Ebola outbreak had brain symptoms more than six months after the initial infection. The preliminary results will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016. [More]
Study: Migraine, tension-type headaches may share genetic links with IBS

Study: Migraine, tension-type headaches may share genetic links with IBS

Migraine and tension-type headaches may share genetic links with irritable bowel syndrome (IBS), according to a preliminary study released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016. [More]
ViiV Healthcare presents positive results from LATTE-2 study at CROI

ViiV Healthcare presents positive results from LATTE-2 study at CROI

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today presented positive results from the LATTE-2 study at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. Headline results were announced in November 2015. [More]
Pfizer’s IBRANCE (palbociclib) now approved for use in women with HR+, HER2- metastatic breast cancer

Pfizer’s IBRANCE (palbociclib) now approved for use in women with HR+, HER2- metastatic breast cancer

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of IBRANCE (palbociclib) 125mg capsules, Pfizer’s metastatic breast cancer therapy. [More]
Worsening migraine no reason to halt dihydroergotamine infusion

Worsening migraine no reason to halt dihydroergotamine infusion

Worsening of headache during intravenous dihydroergotamine treatment for chronic migraine does not mean that the therapy will be unsuccessful, say researchers. [More]
Advertisement
Advertisement